Cutis laxa recessive type 1
Cutis laxa recessive

Contact us
Return to database

We were unfortunately unable to download the information for this disease from OMIM.

Prevalence of clinical parameters (%)

Add new symptom/sign to this disease

Select symptom from list or write it in the box
Pubmed id number as a reference Organ system affected
Number of patients in the reference Percent affected patients (Between 0 and 1, eg. 0.1 = 10%)
Please provide your name and contact information as a reference
Name Institute Phone number Email address

List of symptoms

Symptom/sign Organ system Percent affected Pubmed id Added on(yyyy-mm-dd) Edit/add reference
Cutis laxa integumentary 100 % 22829427 2014-04-24
Emphysema respiratory 92 % 22829427 2014-04-24
Peripheral pulmonary artery stenosis circulatory 50 % 22829427 2014-04-24
Hernia digestive 42 % 22829427 2014-04-24
Diaphragmatic hernia digestive 42 % 22829427 2014-04-24
Hypotonia nervous 42 % 22829427 2014-04-24
Prominent ears integumentary 42 % 22829427 2014-04-24
Inguinal hernia digestive 25 % 22829427 2014-04-24
Tricuspid valvular insufficiency circulatory 25 % 22829427 2014-04-24
Aortic valvular insufficiency circulatory 25 % 22829427 2014-04-24
Bossed forehead skeletal 25 % 22829427 2014-04-24
Broad nasal bridge skeletal 25 % 22829427 2014-04-24
Prominent veins integumentary 25 % 22829427 2014-04-24

List of references:

Comprehensive clinical and molecular analysis of 12 families with type 1 recessive cutis laxa.
Bert Callewaert, Chi-Ting Su, Tim Van Damme, Philip Vlummens, Fransiska Malfait, Olivier Vanakker, Bianca Schulz, Meghan Mac Neal, Elaine C Davis, Joseph G H Lee, Aicha Salhi, Sheila Unger, Ketil Heimdal, Salome De Almeida, Uwe Kornak, Harald Gaspar, Jean-Luc Bresson, Katrina Prescott, Maria E Gosendi, Sahar Mansour, Gérald E Piérard, Suneeta Madan-Khetarpal, Frank C Sciurba, Sofie Symoens, Paul J Coucke, Lionel Van Maldergem, Zsolt Urban, Anne De Paepe,

Autosomal recessive cutis laxa type I (ARCL type I) is characterized by generalized cutis laxa with pulmonary emphysema and/or vascular complications. Rarely, mutations can be identified in FBLN4 or FBLN5. Recently, LTBP4 mutations have been implicated in a similar phenotype. Studying FBLN4, FBLN5, and LTBP4 in 12 families with ARCL type I, we found bi-allelic FBLN5 mutations in two probands, whereas nine probands harbored biallelic mutations in LTBP4. FBLN5 and LTBP4 mutations cause a very similar phenotype associated with severe pulmonary emphysema, in the absence of vascular tortuosity or aneurysms. Gastrointestinal and genitourinary tract involvement seems to be more severe in patients with LTBP4 mutations. Functional studies showed that most premature termination mutations in LTBP4 result in severely reduced mRNA and protein levels. This correlated with increased transforming growth factor-beta (TGFβ) activity. However, one mutation, c.4127dupC, escaped nonsense-mediated decay. The corresponding mutant protein (p.Arg1377Alafs(*) 27) showed reduced colocalization with fibronectin, leading to an abnormal morphology of microfibrils in fibroblast cultures, while retaining normal TGFβ activity. We conclude that LTBP4 mutations cause disease through both loss of function and gain of function mechanisms.

Human mutation - Jan 2013